For the Inventor, By the Inventor

Enter assignee name

Rockville, MD, United States of America

Glycomimetics, Inc.

Calculating rank

USPTO Granted Patents = 41

% Expired Patents = 14.6

EPO Patents = 9

Forward Citations = 450

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

John L Magnani (39 out of 48 patents)

Arun K Sarkar (21 out of 22 patents)

John Tinsman Patton, Jr (11 out of 12 patents)

4. Myung-Gi Baek (10 out of 10 patents)

5. John M Peterson (8 out of 11 patents)

6. Yanhong Li (6 out of 6 patents)

7. Beat Ernst (6 out of 13 patents)

8. Frank Elbert Anderson, Iii (6 out of 10 patents)

9. Sergei A Svarovsky (4 out of 7 patents)

10. Leonard M Williams (3 out of 3 patents)

11. Yusufbhai U Vohra (3 out of 3 patents)

12. Yusuf U Vohra (2 out of 2 patents)

13. William E Fogler (2 out of 7 patents)

14. Indranath Ghosh (2 out of 4 patents)

15. Jason Nogueira (2 out of 2 patents)

Core Competencies:

E-Selectin Antagonists

Galectin-3 Inhibitors

Multimeric Compounds

Heterobifunctional Inhibitors

Cancer Treatment

Cardiovascular Disease

Mobilization Methods

Glycomimetic Compounds

Sickle Cell Disease

Pan-Selectin Inhibitors

Chemokine Receptors

Selectin-Mediated Function

41 patents: Sort by Forward Citations

1. 11987598 - E-selectin antagonist compounds, compositions, and methods of use (2024-05-21),

2. 11878026 - Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists (2024-01-23),

3. 11873317 - Galectin-3 inhibiting c-glycosides (2024-01-16),

4. 11845771 - Heterobifunctional inhibitors of E-selectin and galectin-3 (2023-12-19),

5. 11780873 - Highly potent multimeric e-selectin antagonists (2023-10-10),

6. 11712446 - Methods of mobilizing marrow infiltrating lymphocytes and uses thereof (2023-08-01),

7. 11707474 - Methods for treating acute myeloid leukemia and related conditions (2023-07-25),

8. 11548908 - Heterobifunctional inhibitors of E-selectin and galectin-3 (2023-01-10),

9. 11433086 - Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 (2022-09-06),

10. 11332491 - E-selectin antagonist compounds, compositions, and methods of use (2022-05-17),

11. 11291678 - Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin (2022-04-05),

12. 11197877 - Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists (2021-12-14),

13. 11072625 - Highly potent multimeric e-selectin antagonists (2021-07-27),

14. 11045485 - Glycomimetic inhibitors of PA-IL and PA-IIL lectins (2021-06-29),

15. 10766916 - E-selectin antagonist compounds, compositions, and methods of use (2020-09-08),

Company Overview

Glycomimetics, Inc. is a biotechnology company based in Rockville, Maryland, focused on the discovery and development of innovative therapies for serious diseases. The company specializes in glycomimetic compounds that target critical pathways in cancer and cardiovascular diseases. Its core technologies include E-selectin antagonists, galectin-3 inhibitors, and heterobifunctional inhibitors, which are designed to address unmet medical needs, particularly in acute myeloid leukemia and T-cell checkpoint inhibition.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

41 Patents

#16 in Rockville, MD

#98 in Maryland

#8,449 in US

#16,731 in the World

Rockville, MD, United States of America

Glycomimetics, Inc.

Forward Citations = 450

24 inventors:

John L Magnani (39 out of 48 patents)

Arun K Sarkar (21 out of 22 patents)

John Tinsman Patton, Jr (11 out of 12 patents)

4. Myung-Gi Baek (10 out of 10 patents)

5. John M Peterson (8 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Glycomimetics, Inc.. Retrieved from https://idiyas.com/company/glycomimetics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…